CiVi Biopharma develops oral antisense oligonucleotide therapies targeting hypercholesterolemia and atherosclerotic cardiovascular disease, utilizing third-generation PCSK9 antisense molecules. The company also advances intravenous formulations of iloprost for treating severe frostbite, addressing critical needs in cardiovascular and inflammatory conditions.
Funding
$49M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for high cholesterol often fail to achieve target LDL levels, leaving a significant unmet need in preventing heart attacks and strokes caused by atherosclerotic plaque buildup. Existing PCSK9 therapies face barriers due to high prices and inconvenient dosing, limiting broad use. Severe frostbite lacks effective treatments to promote vasodilation and prevent tissue damage.
Solution
CiVi Biopharma develops novel therapies for cardiovascular and inflammatory diseases. CiVi 008 is a third-generation, orally administered PCSK9 antisense molecule designed to lower LDL-cholesterol by blocking PCSK9 synthesis in the liver, offering a more convenient and cost-effective alternative to existing injectable antibody therapies. CiVi 008 targets both major and minor cellular pathways, potentially improving outcomes in patients who do not respond to monoclonal antibodies. CiVi 030 is an intravenous formulation of iloprost, a vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects, being developed for the treatment of severe frostbite to improve blood flow and tissue recovery.
Target Audience
The primary target audiences are patients with hypercholesterolemia and atherosclerotic cardiovascular disease, as well as individuals suffering from severe frostbite.
Features
- CiVi 008: Oral PCSK9 antisense molecule targeting mRNA to block PCSK9 synthesis.
- CiVi 008: Blocks both major and minor cellular pathways for PCSK9 inhibition.
- CiVi 008: Demonstrated dose-responsive PCSK9 knockdown and reduction in atherogenic lipoproteins in early clinical studies (subcutaneous formulation).
- CiVi 008: Aims for improved stability profile and lower cost of goods compared to monoclonal antibodies (mAbs) and inclisiran.
- CiVi 030: Intravenous iloprost formulation for severe frostbite treatment.
- CiVi 030: Promotes vasodilation, inhibits platelet aggregation, and exerts anti-inflammatory and anti-fibrotic effects.